Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 18/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 18/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | USP9X | Q93008 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | FRK | P42685 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1257163 | 0.76 | CSNK1D (0.51) | CSNK1DCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL4826110 | 0.73 | MAPT (0.48) | CSNK1DCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL4826105 | 0.73 | MAPT (0.48) | CSNK1DCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL23160878 | 0.72 | CSNK1D (0.48) | CSNK1DCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL10432598 | 0.72 | CSNK1D (0.48) | CSNK1DCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL4286489 | 0.70 | CSNK1D (0.58) | CSNK1DCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL29902509 | 0.70 | CSNK1D (0.48) | CSNK1DCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL22309898 | 0.70 | SLC6A4 (0.50) | CSNK1DCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL4829307 | 0.69 | CSNK1D (0.54) | CSNK1DCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL25107502 | 0.69 | USP9X (0.45) | USP9X |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | USP9X, USP19, USP39 | CSNK1D 797/4885CSNK1E 478/4885MAPK13 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.